Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-3.52 · Revenue $426250.00 · 2 analysts
Est. EPS $-3.50 · Revenue $413500.00 · 1 analysts
Est. EPS $-16.41 · Revenue $985200.00 · 2 analysts
Est. EPS $-2.00 · Revenue $100000.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $7.7M | +0.1% | -80.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-33.4M | +47.1% | -6.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +80.6% | -19.4% | +114.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -450.1% | +52.6% | -472.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -433.7% | +47.2% | -454.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-39.9M | +34.9% | +18.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -518.8% | +34.9% | -324.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 86.6% | +96.5% | +52.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.59x | +11.9% | -25.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $56.7M | -43.0% | -16.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -17.85 vs -21.23 | +15.9% | -4.57 vs -3.39 | -34.9% |
| Revenue Surprise | $7.7M vs $5.9M | +31.2% | $5000 vs $500000 | -99.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Berner Laura | director | Stock Option (Right to Buy) | A | 5,000 | $4.43 |
| Jun 10, 2026 | LAPORTE KATHLEEN | director | Stock Option (Right to Buy) | A | 5,000 | $4.43 |
| Jun 10, 2026 | Dupont Jakob | director | Stock Option (Right to Buy) | A | 5,000 | $4.43 |
| Jun 10, 2026 | O'CALLAGHAN BRIAN | director | Stock Option (Right to Buy) | A | 5,000 | $4.43 |
| Jun 10, 2026 | ONETTO NICOLE | director | Stock Option (Right to Buy) | A | 5,000 | $4.43 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
William Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary & Director | USD 665,200 | Male | 1971 | Active |
Grant Yonehiro | Chief Operating Officer & Chief Business Officer | USD 602,600 | Male | 1964 | Active |
Michael N. Alonso | Senior Vice President of Research | — | — | — | Active |
Justin Kenkel | Senior Principal Scientist | — | Male | — | Active |
Sarah Nemec | Senior Vice President of Finance & Principal Accounting Officer | — | Female | 1977 | Active |
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, 2025, and the definitive option agreement dated May 12, 2026, as amended (the "Option Agreement"), with Max Iron Brazil Ltd. ("MaxIron"), an entity controlled by Max Resource Corp. ("Max"), pursuant to which Bolt has the right to acquire 100% of the Florália High Purity Iron Property (title no.
